九芝堂(000989.SZ)擬向併購基金追加投資1.5億元
格隆匯 7 月 23日丨九芝堂(000989.SZ)公佈，公司於2020年7月23日召開第七屆董事會第二十二次會議，審議通過了《關於向併購基金追加投資認購基金份額暨關聯交易的議案》。公司根據戰略規劃與投資計劃，決定以自有資金向併購基金珠海橫琴九芝堂雍和啟航股權投資基金(有限合夥)追加投資人民幣1.5億元，以認購併購基金份額。公司此次追加投資後，併購基金總規模為人民幣9億元，其中，普通合夥人北京納蘭德認繳總額為人民幣900萬元；有限合夥人九芝堂股份有限公司認繳總額為人民幣6億元；未來將引入的有限合夥人認繳總額為人民幣2.91億元。議案獲得董事會審議批准後，公司及北京納蘭德將就追加投資事項重新簽署《珠海橫琴九芝堂雍和啟航股權投資基金(有限合夥)合夥協議》。
根據併購基金投資計劃，此次基金將主要把資金投向其參股公司StemedicaCell Technologies Inc.(Stemedica公司)，用於繼續履行雙方已簽署的增資協議，此次計劃投資金額為2100萬美元，將根據併購基金與Stemedica公司的約定分步實施。
公司通過此次投資將滿足目前Stemedica業務發展對資金的需求，同時將通過併購基金提升對Stemedica公司的影響力，加快Stemedica公司研發進程，進一步提升其與北京美科協同性效應，進而推動上市公司幹細胞業務體系發展戰略實施。此次投資使用公司自有資金，不影響公司正常的生產經營活動。
由於併購基金投資的Stemedica公司目前尚未產生盈利，處於虧損狀態，此次投資後，隨着公司間接持有Stemedica公司股權比例進一步增加，Stemedica公司的虧損金額對公司淨利潤的影響將增大。同時，隨着投資分步實施，併購基金對Stemedica公司控制力逐步提升，根據會計準則要求，併購基金可能將Stemedica公司納入其合併報表。此次投資帶來的上述影響不會對公司財務及經營狀況產生重大不利影響,此次投資不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
